Brilliant End of Year report !!! GO HEMO GO30 Apr 2026 16:19
Hemogenyx Pharmaceuticals plc https://hemogenyx.com (https://hemogenyx.com/)
Dr Vladislav Sandler, Chief Executive Officer & Co-Founder headquarters@hemogenyx.com (mailto:headquarters@hemogenyx.com)
Peter Redmond, Director peter.redmond@hemogenyx.com (mailto:peter.redmond@hemogenyx.com)
SP Angel Corporate Finance LLP Tel: +44 (0)20 3470 0470
Matthew Johnson, Vadim Alexandre, Adam Cowl
AlbR Capital Limited Tel: +44 (0)20 7469 0930
Lucy Williams, Duncan Vasey, Charles Goodfellow
Chairman's Statement
It is my privilege to present the Chairman's statement for Hemogenyx
Pharmaceuticals plc (the "Company", and together with its subsidiaries, the
"Group") for the financial year ended 31 December 2025.
In last year's report, I described 2024 as a pivotal period of transition. If
2024 was the year in which Hemogenyx became a clinical-stage company, 2025 was
the year in which we proved that we can operate as one. Against a continuing
backdrop of tight capital markets for small-cap biotechnology, we dosed our
first three patients, generated the earliest signals of efficacy for HG-CT-1,
secured regulatory clearance to expand into paediatrics, forged strategic
partnerships in manufacturing, clinical operations and early
commercialisation, and set the trial on a clear path to dose escalation. These
are the milestones that, taken together, define a clinical-stage company
beginning to deliver.
We have achieved these milestones despite market conditions and challenges in
accessing capital. Ultimately, we were able to do this through a series of
small tranches raised in a combination of equity placings, convertible loan
notes and warrant exercises requiring frequent engagement with brokers and
supportive shareholders. We are particularly grateful for the support of some
of our long term shareholders; with their help, we raised a significant sum -
£2.5 million after the year end. This financing in itself would take us
through and beyond the next phase of our Phase 1 trials, which involves the
treatment of a further three patients with an escalated dose. In addition, we
have just announced the raise of a further equity raise of £3 million, which
we believe will be sufficient to allow us to take the full Phase 1 trials to
completion. Full details of these capital raises are provided in note 26 of
these accounts. The Board has been candid about the capital we needed to see
the Phase I clinical trials through to completion, and about the discipline
with which that capital must be deployed. Each successful step on the way
through those trials helps to validate our progress.
In addition, we have now taken significant steps, including the engagement of
an outside manufacturer, to reduce and manage our future operating costs. The
substantial savings to operating
Sign In
Follow the stocks
